Antitumor Effect of Apcin on Endometrial Carcinoma via p21-Mediated Cell Cycle Arrest and Apoptosis
作者机构：Department of Obstetrics and GynecologyRenmin Hospital of Wuhan UniversityWuhan430060China Institute of Reproductive HealthTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430030China
出 版 物：《Current Medical Science》 (当代医学科学（英文）)
年 卷 期：2024年第44卷第3期
页 面：623-632页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：endometrial carcinoma CDC20 apoptosis cell cycle arrest p21 BBC3
摘 要：Objective Endometrial carcinoma(EC)is a prevalent gynecological malignancy characterized by increasing incidence and mortality *** underscores the critical need for novel therapeutic *** such potential target is cell division cycle 20(CDC20),which has been implicated in *** study investigated the effect of the CDC20 inhibitor Apcin on EC and elucidated the underlying mechanism *** The effects of Apcin on EC cell proliferation,apoptosis,and the cell cycle were evaluated using CCK8 assays and flow *** sequencing(RNA-seq)was subsequently conducted to explore the underlying molecular mechanism,and Western blotting and coimmunoprecipitation were subsequently performed to validate the *** studies were performed to evaluate the antitumor effects in *** analysis was also conducted to identify CDC20 as a potential therapeutic target in *** Treatment with Apcin inhibited proliferation and induced apoptosis in EC cells,resulting in cell cycle *** associated with apoptosis and the cell cycle were activated following treatment with ***,Apcin treatment led to the upregulation of the cell cycle regulator p21,which was verified to interact with CDC20 and consequently decrease the expression of downstream cyclins in EC *** vivo experiments confirmed that Apcin treatment significantly impeded tumor *** CDC20 expression was observed in EC tissue than in nonmalignant tissue,and increased CDC20 expression in EC patients was associated with shorter overall survival and progress free *** CDC20 is a novel molecular target in EC,and Apcin could be developed as a candidate antitumor drug for EC treatment.
维普期刊数据库